TD Asset Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

TD Asset Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53,575	Closed	-$5.75M	–	1491
2023 Q1	$5.75M	Buy	53,575 +12,224	+30%	+$1.41M	0.01%	714
2022 Q4	$4.55M	Buy	41,351 +24,751	+149%	+$1.61M	0.01%	771
2022 Q3	$955K	Buy	+16,600	New	+$760K	﹤0.01%	1191
2021 Q2	–	Sell	-34,465	Closed	-$629K	–	1590
2021 Q1	$629K	Buy	+34,465	New	+$712K	﹤0.01%	1361

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

TD Asset Management's RXDX Position: Q2 2023 in Review

TD Asset Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 53,575 shares — an estimated $5.75M sold.

TD Asset Management first reported a position in RXDX in Q1 2021 and held it in 4 quarters. The position peaked at $5.75M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

TD Asset Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
TD Asset Management sold 53,575 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $5.75M.
TD Asset Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
TD Asset Management's Prometheus Biosciences, Inc. Common Stock position peaked at $5.75M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on TD Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.